Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in Persistent/Chronic Primary Immune Thrombocytopenia
NCT04278924Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of mezagitamab in primary immune thrombocytopenia (ITP), sponsored by Takeda. Started Nov 2020; status: completed.
02
Drugs
mezagitamab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04278924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278924.